New Suitors Prey on Onyx Pharmaceuticals, Inc.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Onyx Pharmaceuticals Inc (ONXX.O) is expected to receive first-round offers as soon as this week after attracting takeover interest from a few drugmakers including Amgen Inc (AMGN.O), according to several people familiar with the matter. Amgen, whose preliminary offer of $120 per share was rejected by Onyx's board in late June and led to an auction of the company, is still keen to buy Onyx and appears to be the more likely buyer, the people said this week. Other pharmaceutical companies including Pfizer (PFE.N), Bristol-Myers Squibb Co (BMY.N) and Gilead Sciences Inc (GILD.O) have also been evaluating a deal, though it remains unclear if those parties will ultimately proceed with offers, the people cautioned.

Help employers find you! Check out all the jobs and post your resume.

Back to news